MSC therapy attenuates obliterative bronchiolitis after murine bone marrow transplant

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Raza, Kashif ^a,d   Larsen, Trevor ^b   Samaratunga, Nath ^b   Price, Andrew P ^c   Meyer, Carolyn ^c   Matson, Amy ^c,e   Ehrhardt, Michael J ^c   Fogas, Samuel ^c   Tolar, Jakub ^c   Hertz, Marshall I ^a   Panoskaltsis Mortari, Angela ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Breck School   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; HYDROXYPROLINE;

AIRWAY RESISTANCE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHIOLITIS OBLITERANS; CELL THERAPY; CONTROLLED STUDY; ECTOPIC TISSUE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY DISEASE; INSPIRATORY CAPACITY; LUNG COMPLIANCE; LUNG FUNCTION TEST; MACROPHAGE; MESENCHYMAL STROMA CELL; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; RESPIRATORY TRACT INJURY; SPLEEN CELL; ANIMAL; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL TRANSPLANTATION;

MURINAE;

ANIMALS; BRONCHIOLITIS OBLITERANS; FEMALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; TRANSPLANTATION CONDITIONING;

EID: 84907554426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109034     Document Type: Article

References (57)

1. Christie JD, Edwards LB, Kucheryavaya A.Y., Aurora P., Dobbels F, et al. (2010) The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 29: 1104-1118.
2. Panoskaltsis-Mortari A, Griese M, Madtes D.K., Belperio JA, Haddad IY, et al. (2011) An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med 183: 1262-1279
3. Williams KM, Hnatiuk O, Mitchell SA, Baird K, Gadalla SM, et al. (2014) NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT. Bone Marrow Transplant 49: 561-566.
4. Belperio JA, Weigt SS, Fishbein M.C., Lynch JP 3rd (2009) Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 6: 108-121.
5. Panoskaltsis-Mortari A, Tram KV, Price A.P., Wendt CH, Blazar B.R. (2007) A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med 176: 713-723.
6. Di Nicola M, Carlo-Stella C, Magni M., Milanesi M, Longoni PD, et al. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838-3843.
7. Burr SP, Dazzi F, Garden O.A. (2013) Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? Immunol Cell Biol 91: 12-18.
8. Tiemessen MM, Jagger AL, Evans H.G., van Herwijnen MJ, John S, et al. (2007) CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A 104: 19446-19451.
9. Casiraghi F, Azzollini N, Cassis P., Imberti B, Morigi M, et al. (2008) Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 181: 3933-3946.
10. Ge W, Jiang J, Baroja M.L., Arp J., Zassoko R, et al. (2009) Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 9: 1760-1772.
11. Madec AM, Mallone R, Afonso G., Abou Mrad E, Mesnier A, et al. (2009) Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52: 1391-1399.
12. McAuley DF, Curley GF, Hamid U.I., Laffey JG, Abbott J, et al. (2014) Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol 306: L809-815.
13. Le Blanc K, Rasmusson I, Sundberg B., Gotherstrom C, Hassan M, et al. (2004) Treatment of severe acute graft-versus-host disease with third party haploiden-tical mesenchymal stem cells. Lancet 363: 1439-1441.
14. Le Blanc K, Frassoni F, Ball L., Locatelli F, Roelofs H, et al. (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579-1586.
15. Yin F, Battiwalla M, Ito S., Feng X, Chinian F, et al. (2014) Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses. Stem Cells 32: 1278-1288.
16. Moermans C, Lechanteur C, Baudoux E., Giet O, Henket M, et al. (2014) Impact of Cotransplantation of Mesenchymal Stem Cells on Lung Function After Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Following Non-Myeloablative Conditioning. Transplantation.
17. Sinclair K, Yerkovich ST, Chambers D.C. (2013) Mesenchymal stem cells and the lung. Respirology 18: 397-411.
18. Weiss DJ, Kolls JK, Ortiz L.A., Panoskaltsis-Mortari A, Prockop D.J. (2008) Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 5: 637-667.
19. Weiss DJ, Bates JH, Gilbert T, Liles W.C., Lutzko C., et al. (2013) Stem cells and cell therapies in lung biology and diseases: conference report. Ann Am Thorac Soc 10: S25-44.
20. Antunes MA, Laffey JG, Pelosi P, Rocco P.R. (2014) Mesenchymal stem cell trials for pulmonary diseases. J Cell Biochem 115: 1023-1032.
21. Peister A, Mellad JA, Larson B.L., Hall BM, Gibson LF, et al. (2004) Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103: 1662-1668.
22. Tolar J, Nauta AJ, Osborn M.J., Panoskaltsis Mortari A, McElmurry RT, et al. (2007) Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25: 371-379.
23. Hebbel RP, Vercellotti GM, Pace B.S., Solovey AN, Kollander R, et al. (2010) The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood 115: 2483-2490.
24. Baglole CJ, Reddy SY, Pollock S.J., Feldon SE, Sime PJ, et al. (2005) Isolation and Phenotypic Characterization of Lung Fibroblasts. Methods in Molecular Medicine 117: 115-127.
25. Bucher C, Koch L, Vogtenhuber C., Goren E, Munger M, et al. (2009) IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood 114: 5375-5384.
26. Kebriaei P, Robinson S. (2011) Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease. Front Oncol 1: 16.
27. Sundin M, Barrett AJ, Ringden O, Uzunel M., Lonnies H, et al. (2009) HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 32: 755-764.
28. Vaes B, Van't Hof W, Deans R, Pinxteren J (2012) Application of MultiStem((R)) Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease. Front Immunol 3: 345.
29. Isakova IA, Lanclos C, Bruhn J., Kuroda MJ, Baker KC, et al. (2014) Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo. PLoS One 9: e87238.
30. Sivanathan KN, Gronthos S, Rojas-Canales D, Thierry B., Coates P.T. (2014) Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Rev 10: 351-375.
31. Perico N, Casiraghi F, Introna M., Gotti E, Todeschini M, et al. (2011) Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 6: 412-422.
32. Chambers DC, Enever D, Ilic N., Sparks L, Whitelaw K, et al. (2014) A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology.
33. Weiss DJ, Casaburi R, Flannery R., LeRoux-Williams M, Tashkin D.P. (2013) A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 143: 1590-1598.
34. Tzouvelekis A, Paspaliaris V, Koliakos G., Ntolios P, Bouros E, et al. (2013) A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med 11: 171.
35. Goerdt S, Orfanos C.E. (1999) Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10: 137-142.
36. Workman CJ, Szymczak-Workman AL, Collison L.W., Pillai MR, Vignali D.A. (2009) The development and function of regulatory T cells. Cell Mol Life Sci 66: 2603-2622.
37. Zhao Y, Gillen JR, Harris D.A., Kron IL, Murphy MP, et al. (2014) Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model. J Thorac Cardiovasc Surg 147: 1668-1677 e1665.
38. Kim J, Hematti P. (2009) Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 37: 1445-1453.
39. Maggini J, Mirkin G, Bognanni I., Holmberg J, Piazzon IM, et al. (2010) Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 5: e9252.
40. Guth AM, Janssen WJ, Bosio C.M., Crouch EC, Henson PM, et al. (2009) Lung environment determines unique phenotype of alveolar macrophages. Am J-Physiol Lung Cell Mol Physiol 296: L936-946.
41. Guo Z, Zhou X, Li J., Meng Q, Cao H, et al. (2013) Mesenchymal stem cells reprogram host macrophages to attenuate obliterative bronchiolitis in murine orthotopic tracheal transplantation. Int Immunopharmacol 15: 726-734.
42. Grove DA, Xu J, Joodi R., Torres-Gonzales E, Neujahr D, et al. (2011) Attenuation of early airway obstruction by mesenchymal stem cells in a murine model of heterotopic tracheal transplantation. J Heart Lung Transplant 30: 341-350.
43. Betancourt AM (2013) New Cell-Based Therapy Paradigm: Induction of Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells into Pro-Inflammatory MSC1 and Anti-inflammatory MSC2 Phenotypes. Adv Biochem Eng Biotechnol 130: 163-197.
44. Islam MN, Das SR, Emin M.T., Wei M., Sun L, et al. (2012) Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 18: 759-765.
45. Behr J, Maier K, Braun B., Schwaiblmair M, Vogelmeier C. (2000) Evidence for oxidative stress in bronchiolitis obliterans syndrome after lung and heart-lung transplantation. The Munich Lung Transplant Group. Transplantation 69: 1856-1860.
46. Madill J, Aghdassi E, Arendt B., Hartman-Craven B, Gutierrez C, et al. (2009) Lung transplantation: does oxidative stress contribute to the development of bronchiolitis obliterans syndrome? Transplant Rev (Orlando) 23: 103-110.
47. Stober VP, Szczesniak C, Childress Q., Heise RL, Bortner C, et al. (2014) Bronchial epithelial injury in the context of alloimmunity promotes lymphocytic bronchiolitis through hyaluronan expression. Am J Physiol Lung Cell Mol Physiol 306: L1045-1055.
48. Ziegler TR, Panoskaltsus-Mortari A, Gu L.H., Jonas CR, Farrell CL, et al. (2001) Regulation of glutathione redox status in lung and liver by conditioning regimens and keratinocyte growth factor in murine allogeneic bone marrow transplantation. Transplantation 72: 1354-1362.
49. Nauta AJ, Westerhuis G, Kruisselbrink A.B., Lurvink EG, Willemze R, et al. (2006) Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108: 2114-2120.
50. Foskett AM, Bazhanov N, Ti X., Tiblow A, Bartosh TJ, et al. (2014) Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs. Am J Physiol Lung Cell Mol Physiol 306: L120-131.
51. Danchuk S, Ylostalo JH, Hossain F, Sorge R., Ramsey A, et al. (2011) Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6. Stem Cell Res Ther 2: 27.
52. Qi Y, Jiang D, Sindrilaru A., Stegemann A, Schatz S, et al. (2014) TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol 134: 526-537.
53. Ware LB, Matthay M.A. (2002) Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol 282: L924-940.
54. Panoskaltsis-Mortari A, Ingbar DH, Jung P, Haddad I.Y., Bitterman PB, et al. (2000) KGF pretreatment decreases B7 and granzyme B expression and hastens repair in lungs of mice after allogeneic BMT. Am J Physiol Lung Cell Mol Physiol 278: L988-999.
55. Moodley Y, Vaghjiani V, Chan J., Baltic S, Ryan M, et al. (2013) Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study. PLoS One 8: e69299.
56. Ortiz LA, Dutreil M, Fattman C., Pandey AC, Torres G, et al. (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 104: 11002-11007
57. Meisel R, Brockers S, Heseler K, Degistirici O, Bulle H, et al. (2011) Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 25: 648-654.